Emin Taşkıran

Emin Taşkıran

Auto-generated profile, based on publicly available information

Emin Taşkıran

Department of Internal Medicine, Tepecik Training and Research Hospital, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2018 in BMC Neurology
Verified
Journal Article
Open access
PDF file
MEMumin Alper Erdogan
Mumin Alper Erdogan
DYDimas Yusuf
Dimas Yusuf
JCJoanna Christy
Joanna Christy
VSVolkan Solmaz
Volkan Solmaz
AEArife Erdogan
Arife Erdogan
OEOytun Erbas
Oytun Erbas
Worldwide, over 10 million individuals suffer from drug-resistant epilepsy. New therapeutic strategies are needed to address this debilitating disease. Inhibition of sodium-glucose linked transporters (SGLTs), which are variably expressed in the brain, has been demonstrated to reduce seizure activity in murine models of epilepsy. Here we investigated the effects of dapagliflozin, a highly competitive SGLT2 inhibitor currently used as a drug for diabetes mellitus, on seizure activity in rats with pentylenetetrazol (PTZ) induced seizures. Laboratory rats (n = 48) were evenly randomized into two experiments, each with four study arms: (1) a vehicle-treated (placebo) arm infused with saline; (2) a control arm infused with PTZ; (3) a treatment arm with PTZ and dapagliflozin at 75 mg/kg, and (4) another treatment arm with PTZ and dapagliflozin at 150 mg/kg. Study subjects were assessed for seizures either via EEG as measured by spike wave percentage (SWP), or clinically via Racine’s scales scores (RSS) and time to first myoclonic jerk (TFMJ). Rats treated with dapagliflozin had lower mean SWP on EEG (20.4% versus 75.3% for untreated rats). Behaviorally, treatment with dapagliflozin improved means RSS (2.33 versus 5.5) and mean TFMJ (68.3 versus 196.7 s). All of these findings were statistically significant with p-values of < 0.0001. There was a trend towards even better seizure control with the higher dose of dapagliflozin at 150 mg/kg, however this was not consistently statistically significant. Dapagliflozin decreased seizure activity in rats with PTZ–induced seizures. This may be explained by the anti-seizure effects of decreased glucose availability and a reduction in sodium transport across neuronal membranes which can confer a stabilizing effect against excitability and unwanted depolarization. The potential clinical role of dapagliflozin and other SGLT2 inhibitors as anti-seizure medications should be further explored.

4 November 2019 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
PDF file
MEMumin Alper Erdogan
Mumin Alper Erdogan
ETEmin Taşkıran
Emin Taşkıran
GYGürkan Yiğittürk
Gürkan Yiğittürk
OEOytun Erbaş
Oytun Erbaş
DTDilek Taskiran
Dilek Taskiran


18 October 2022 in European Journal of Geriatrics and Gerontology
Verified
Journal Article
Open access
FKFatma Ozge Kayhan Kocak
Fatma Ozge Kayhan Kocak
ETEmin Taşkıran
Emin Taşkıran
SŞSevnaz Şahin
Sevnaz Şahin

17 February 2022 in Experimental Aging Research
Verified
Journal Article
Closed access
FKFatma Ozge Kayhan Kocak
Fatma Ozge Kayhan Kocak
SSSevnaz Sahin
Sevnaz Sahin
ETEmin Taşkıran
Emin Taşkıran
HSHatice Simsek
Hatice Simsek
ADAyse Daylan
Ayse Daylan
SASelahattin Fehmi Akcicek
Selahattin Fehmi Akcicek
We aimed to evaluate frequency and risk factors of re-hospitalization which are not stated in comorbidity indexes in geriatric wards.A total of 585 patients who were admitted to tertiary care geria...

17 January 2017 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
ETE. Taşkıran
E. Taşkıran
MTM. Yaşar Taş
M. Yaşar Taş
BHBurcu Ozturk Hismi
Burcu Ozturk Hismi
FIF. Demet İnce
F. Demet İnce
SES. Ekmekçi
S. Ekmekçi
HAH. Akar
H. Akar